Abstracts tagged "B cells and rheumatoid arthritis (RA)"

Abstract Number: 78 • 2018 ACR/ARHP Annual Meeting
Decreased B Cell Ataxia-Telangiectasia Mutated Expression and Receptor Diversity Identify a Subset of Rheumatoid Arthritis Patients with Increased Joint Erosion Prevalence
Kofi Mensah¹, Jean-Nicolas Schickel², Isabel Isnardi² and Eric Meffre², ¹Section of Rheumatology, Yale University School of Medicine, New Haven, CT, ²Department of Immunobiology, Yale University School of Medicine, New Haven, CT
Background/Purpose: A skewed B cell receptor (BCR) repertoire was observed in some RA patients. In these patients, BCR κ light chains contain a higher percentage…
Abstract Number: 836 • 2017 ACR/ARHP Annual Meeting
B Cell Receptor Sequencing of Anti-Citrullinated Protein Antibody Expressing B Cells Indicates a Selective Advantage for the Introduction of N-Glycosylation Sites during Somatic Hypermutation
Rochelle D. Vergroesen¹, Linda Slot¹, Lise Hafkenscheid¹, Marvyn T. Koning², Ellen I.H. van der Voort³, Christine A. Grooff¹, George Zervakis², Tom W.J. Huizinga¹, Theo Rispens⁴, Hendrik Veelken², Rene E.M. Toes¹ and Hans U. Scherer³, ¹Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ²Hematology, Leiden University Medical Center, Leiden, Netherlands, ³Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ⁴Immunopathology, Sanquin Research, Amsterdam, Netherlands
Background/Purpose: The vast majority (>90%) of anti-citrullinated protein antibodies (ACPA) of the IgG isotype in serum and synovial fluid of patients with rheumatoid arthritis carry…
Abstract Number: 2111 • 2016 ACR/ARHP Annual Meeting
Generation and Characterization of Anti-Citrullinated Protein Antibody-Producing B-Cell Clones
Kristine Germar^1,2, Mark Kwakkenbos³, Sabrina Pollastro^1,2, Nathalie van Uden^1,2,4, Priscilla Kerkman⁵, Ellen I.H. van der Voort⁶, Evan Reed⁷, Karin Lundberg⁷, Niek de Vries^1,8, Lars Klareskog⁷, Hans U. Scherer⁵, René E.M. Toes⁵, Arjen Bakker³, Hergen Spits^3,9,10 and Dominique Baeten^1,2,10, ¹Clinical Immunology and Rheumatology, Academic Medical Center/University of Amsterdam, Amsterdam, Netherlands, ²Amsterdam Rheumatology and immunology Center, Amsterdam, Netherlands, ³AIMM Therapeutics, Amsterdam, Netherlands, ⁴Experimental Immunology, Academic Medical Center/University of Amsterdam, Amsterdam, Netherlands, ⁵Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ⁶Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ⁷Rheumatology Unit, Department of Medicine, Karolinska Institutet, Stockholm, Sweden, ⁸Clinical Immunology and Rheumatology F4-105, Amsterdam Rheumatology and immunology Center, location AMC, Amsterdam, Netherlands, ⁹Department of Cell Biology and Histology, Academic Medical Centre/University of Amsterdam, Amsterdam, Netherlands, ¹⁰These authors contributed equally to this work, Amsterdam, Netherlands
Background/Purpose: Rheumatoid arthritis (RA) is the most frequent form of autoimmune arthritis with a prevalence of almost 1% worldwide. Anti-citrullinated protein antibodies (ACPA) are the…
Abstract Number: 2408 • 2013 ACR/ARHP Annual Meeting
Secretory Leukocyte Protease Inhibitor Released By Rheumatoid Synovial Fibroblasts Exerts a Negative Control Of BAFF-Dependent B Cell Activation In Vitro and In Vivo In The Collagen-Induced and Chimeric RA/SCID Arthritis Models
Yvonne NW Kam¹, Andrew Filer², Christopher D. Buckley³, Costantino Pitzalis⁴ and Michele Bombardieri⁵, ¹William Harvey Research Institute, Centre for Experimental Medicine and Rheumatology, QMUL, London, United Kingdom, ²Rheumatology Research Group, MRC Centre for Immune Regulation, School of Immunity and Infection, University of Birmingham, Birmingham, United Kingdom, ³Rheumatology Research Group, University of Birmingham Research Laboratories, University of Birmingham, Birmingham, United Kingdom, ⁴Centre for Experimental Medicine and Rheumatology, William Harvey Research Institute, QMUL, London, United Kingdom, ⁵Centre for Experimental Medicine and Rheumatology, William Harvey Research Institute, Queen Mary University of London, London, United Kingdom
Background/Purpose: Rheumatoid arthritis (RA) is characterized by the formation of synovial niches of autoreactive B cells which are favored by the autocrine production of B…
Abstract Number: 1276 • 2012 ACR/ARHP Annual Meeting
Changes in B Cell Populations and Serum Immunoglobulins and Their Relationship to Infections in a One Year, Uncontrolled Open Label Study of Tabalumab
Maria W. Greenwald¹, Melissa Veenhuizen², Wendy Komocsar³, Rebecca Jones-Taha⁴, Chin H. Lee³ and Pierre-Yves Berclaz³, ¹Desert Medical Advances, Palm Desert, CA, ²Eli Lilly and Company, Indianapolis, IN, ³Eli Lilly & Company, Indianapolis, IN, ⁴PharmaNet/i3, Blue Bell, PA
Background/Purpose: B cell activating factor (BAFF) is an important modulator of B cell development and proliferation and is secreted by neutrophils, monocytes, macrophages and dendritic…
Abstract Number: 2667 • 2012 ACR/ARHP Annual Meeting
Activated Memory B Cell Compartment in Rheumatoid Arthritis: Impact of B Cell Depletion Therapy
Diana G. Adlowitz¹, Jennifer Hossler¹, Jamie Biear², Christopher A. Cistrone¹, Teresa Owen¹, Wensheng Wang¹, Arumugam Palanichamy¹, Ignacio Sanz³ and Jennifer H. Anolik¹, ¹Medicine- Allergy, Immunology and Rheumatology, University of Rochester Medical Center, Rochester, NY, ²Allergy, Immunology and Rheumatology, University of Rochester, Rochester, NY, ³Allergy, Immunology and Rheumatology, Emory University School of Medicine, Atlanta, GA
Background/Purpose: B cells are critical players in the orchestration of properly regulated immune responses. This is achieved through the finely regulated participation of multiple B…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].